The European Commission rejects the use of terbutryn, BIT and TMAD in biocides for material preservation and pest control. Manufacturers must withdraw or reformulate their products.
The European Commission approves that U.S. companies may apply for contracts from the European fund to rebuild Ukraine. This opens competition to U.S. firms in tenders financed by the EU.
The CETA Joint Committee clarifies how to interpret the investor protection rules of the trade agreement between the EU and Canada. It affects companies that invest or trade between both territories.
The EU-Canada agreement committee approves an accelerated procedure to resolve conflicts between investors or SMEs and States. It facilitates access to international arbitral justice for smaller businesses.
The European Commission modifies the list of Chinese animal products subject to special import controls. It affects importers and operators working with these products in the EU.
The EU Council modifies the list of products that can be imported with reduced or zero tariff. It affects companies that import agricultural and industrial raw materials from third countries.
The EU modifies which implantable medical products and class III devices are exempt from mandatory clinical research requirements. Affects manufacturers of high-risk medical devices.
The EU modifies which medium-high risk medical implants are exempt from case-by-case documentary review. Affects manufacturers and notified bodies in the healthcare sector.
Technical errors in the European regulation establishing sanctions against Russia are corrected. The changes are of a formal nature and do not alter the substance of the restrictive measures.
The EU imposes definitive anti-dumping tariffs on 1,4-butanediol imported from China, Saudi Arabia and USA to protect European producers from unfair competition.